Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for WellPoint, Inc. (now Elevance Health, Inc.) for the period ended September 30, 2007. WellPoint is the largest health benefits company in the United States by commercial membership, serving approximately 34.8 million members. The company operates through three reportable segments: Commercial and Consumer Business (CCB), Specialty, Senior and State-Sponsored Business (4SB), and Other. The company announced a new organizational structure effective January 1, 2008, consolidating operations into Commercial, Consumer, and Comprehensive Health Solutions units.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 |
|---|---|---|
| Total Revenues | $15,233.9 million | $45,572.9 million |
| Net Income | $868.0 million | $2,486.3 million |
| Diluted EPS | $1.45 | $4.06 |
| Operating Cash Flow | N/A | $3,240.3 million |
| Total Assets | $52,899.7 million | N/A |
| Total Liabilities | $29,225.8 million | N/A |
| Shareholders' Equity | $23,673.9 million | N/A |
| Long-Term Debt | $8,381.0 million | N/A |
| Cash and Equivalents | $2,824.0 million | N/A |
Margins: The benefit expense ratio was 81.8% for the quarter and 82.2% for the nine-month period. The selling, general, and administrative (SG&A) expense ratio was 14.6% for the quarter and 14.7% for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total operating revenue increased 5% ($744.7 million) for the quarter and 7% ($2,987.6 million) for the nine months compared to the prior year periods. Growth was driven by premium rate increases in Local Group, expansion in State-Sponsored business (addition of five new states), and growth in Medicare Advantage.
- Profitability: Net income increased 7% for the quarter and 8% for the nine months. Diluted EPS increased 12% for the quarter and 15% for the nine months, aided by share repurchases reducing the share count.
- Segment Performance:
- CCB Segment: Operating gain increased 17% for the quarter and 11% for the nine months, driven by disciplined pricing outpacing cost of care.
- 4SB Segment: Operating gain decreased 21% for both periods. This decline was primarily due to adjustments to Medicare Part D risk-sharing accruals and higher claims trends in State-Sponsored business.
- Investments: Net investment income increased 16% for both periods due to higher interest rates and reinvestment of cash flows. Net realized gains on investments were $9.5 million for the quarter and $10.6 million for the nine months, compared to $4.6 million and a loss of $11.4 million in the prior year periods, respectively.
Guidance, Outlook, and Risks
Management Commentary: Management maintains a cost of care trend estimate of less than 8% for 2007. The company is focusing on integrating the acquisition of American Imaging Management (AIM) to improve radiology management efficiency. Premium rate increases in California and Connecticut are expected to be effective in late 2007 to address higher medical trends.
Capital Allocation: The company remains committed to its stock repurchase program. During the nine months ended September 30, 2007, it repurchased approximately 54.4 million shares for $4.3 billion. Approximately $624.5 million remained authorized for future repurchases as of the quarter end.
Risks and Contingencies:
- Medical Claims Reserves: The liability for medical claims payable ($5.8 billion) is the most judgmental estimate. A 3% variability in completion factors could result in approximately $199 million of variability in the liability.
- Investment Impairments: The company recorded $150.2 million in other-than-temporary impairment charges for the nine months ended September 30, 2007, primarily related to interest rate and credit-related impairments.
- Legal Proceedings: The company is involved in various litigation, including the Love Litigation (RICO claims) and disputes with John Hancock regarding reinsurance arrangements. Management believes these are unlikely to have a material adverse effect.
- Regulatory: The company is subject to examinations by the IRS and state authorities regarding tax positions and claims handling practices.
Investor Verification Checklist
- Verify the impact of the Medicare Part D risk-sharing accrual adjustments on the 4SB segment's future profitability.
- Monitor the development of medical claims reserves, specifically the "prior year redundancies" which were $336.2 million for the nine months ended September 30, 2007.
- Assess the sustainability of the 8% cost of care trend estimate given rising pharmacy and specialty drug costs.
- Review the status of the Love Litigation settlement and the John Hancock arbitration to confirm no material financial impact.
- Track the execution of the remaining $624.5 million stock repurchase authorization and its effect on future EPS.